ZEUS
Everolimus Conversion in Kidney Transplant Recipients
Patient / Population Intervention / Exposure Comparison Outcome
In 300 kidney-transplant recipients, early conversion from ciclosporin to everolimus improved kidney function compared with continued ciclosporin.
N
300
Design
Open-label RCT
Endpoint
eGFR at 12 months
Relevance
3
Result71.8 vs 61.9 mL/min; +9.8 (p<0.0001); more biopsy-proven rejection with everolimus (10% vs 3%).
Budde K, et al. Lancet. 2011;377(9768):837-847. 10.1016/S0140-6736(10)62318-5
Discussion & critique
Showed mTOR conversion improves function at the cost of more rejection; the benefit was sustained at 5 years.